NCT05390645View on ClinicalTrials.gov

A Study of MFA-370 in Patients with Metastatic Urothelial Cancer

PHASE1/PHASE2WithdrawnINTERVENTIONAL

0

Timeline

Start Date

December 1, 2024

Primary Completion Date

December 1, 2025

Study Completion Date

December 1, 2025

Conditions

Metastatic Urothelial Cancer

Interventions

DRUG

MFA-370

MFA-370 is a treatment with a combination of two approved pharmaceuticals

Trial Locations (1)

Unknown

Karolinska University Hospital, Stockholm

Sponsors

Lead Sponsor

Ectin Research AB

All Listed Sponsors

lead

Ectin Research AB

INDUSTRY

NCT05390645 - A Study of MFA-370 in Patients with Metastatic Urothelial Cancer | Biotech Hunter | Biotech Hunter